🔴 Biovie is trading 9.23% down in pre-market as biotech ETF XBI falls 3.65%

Biovie is trading $1.24, down 9.23% in pre-market on October 20, amid biotech sector weakness.

• The previous close was $1.37; XBI was down 3.65% pre-market.
• No new October 20 company announcement was identified.
• BioVie presented Phase 2 Long COVID results on October 19. In the overall trial population, no endpoint reached statistical significance; positive findings were limited to prespecified subgroups. The results may provide context, but a direct link to the decline is unconfirmed.